Retatrutide TRIUMPH-1 in NEJM: What the Full Phase 3 Paper Reports

What Did the NEJM Publish on 29 September 2026?

On 29 September 2026 the New England Journal of Medicine published online the full report of TRIUMPH-1, the pivotal Phase 3 obesity trial of retatrutide (LY3437943), under the title “Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity”.[1] The trial is registered as NCT05929066 and was funded by Eli Lilly, the developer.[2] The paper appeared on the same day as the TRIUMPH-2 report in The Lancet and Lilly’s retatrutide symposium at EASD 2026 in Milan, which we covered in our TRIUMPH-2 Lancet guide.

For researchers the significance is evidentiary rather than novel: the headline 80-week figures were disclosed in Lilly’s May 2026 topline release and at ADA in June (see our TRIUMPH-1 data summary). A journal paper adds the pre-specified statistical framework, all three dose arms in one place, and full adverse-event tables that a press release does not provide.

How Was TRIUMPH-1 Designed?

The three-dose, placebo-controlled structure makes TRIUMPH-1 the cleanest published dose-response description of a GIP/GLP-1/glucagon triple agonist to date. The Phase 2 trial reported in NEJM in 2023 covered 338 participants over 48 weeks;[3] TRIUMPH-1 is roughly seven times larger and runs 32 weeks longer, which narrows confidence intervals and exposes rarer adverse events.

Why Does the Paper Report Two Different Weight Figures?

Readers comparing news coverage will have seen both 25.0% and 28.3% attached to the 12 mg arm. Both are correct; they are different estimands, a term from the ICH E9(R1) framework that defines precisely which question a trial analysis answers.

The treatment-regimen means for the lower arms were −17.6% (4 mg) and −23.7% (9 mg).[1] The gap between the two estimands reflects participants who stopped or interrupted treatment. Neither figure should be quoted without naming its estimand, and neither should be compared against a figure from another trial unless that trial used the same one. A 104-week extension in the higher-BMI subset was reported by Lilly at −30.3%.[4]

What Tolerability Data Does the Paper Add?

The paper reports gastrointestinal events as the most common adverse events, in line with the incretin class. Nausea was reported by 28.6% (4 mg), 38.4% (9 mg) and 42.4% (12 mg) of retatrutide participants, versus 14.8% with placebo.[1] The monotonic rise across arms is the pattern pharmacologists expect from a dose-dependent receptor-mediated effect.

A separate TRIUMPH-4 signal, dysesthesia, is discussed in our dysesthesia guide; heart-rate and rhythm observations are collected in our cardiovascular signal guide. We could not read the NEJM full text directly at the time of writing, so for any adverse-event category not quoted above, consult the paper’s supplementary tables.

What Does This Mean for Receptor-Pharmacology Research?

Retatrutide is a single peptide engineered to agonise three receptors — GIP, GLP-1 and glucagon. The TRIUMPH-1 dose-response is a published reference point for how that multi-receptor activity behaves at scale, and it is the benchmark that in vitro work on triple agonism is now measured against. For how the three receptors are thought to interact, see our mechanism of action guide.

It bears repeating that TRIUMPH-1 is a pharmaceutical trial of a licensed-pathway drug candidate, run under regulatory oversight. It is categorically separate from research-use reagents, which carry no clinical data of their own and are not for human use. Lilly has said it intends to file a Biologics License Application with the FDA in Q1 2027; see our approval timeline guide. Velox Peptides supplies retatrutide only as an HPLC-verified in vitro research reagent.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions